Palifermin

Drug Profile

Palifermin

Alternative Names: AMJ 9701; Kepivance; Keratinocyte growth factor - Amgen; KGF - Amgen; Recombinant human fibroblast growth factor-7; Recombinant human keratinocyte growth factor; rhFGF-7; rHu-KGF; rhuFGF-7

Latest Information Update: 07 Dec 2016

Price : $50

At a glance

  • Originator Amgen
  • Developer Amgen; Swedish Orphan Biovitrum
  • Class Chemoprotectants; Fibroblast growth factors
  • Mechanism of Action Fibroblast growth factor replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Stomatitis
  • No development reported Graft-versus-host disease; Inflammatory bowel diseases

Most Recent Events

  • 06 Dec 2016 No recent reports on development identified - Phase-II for Graft-versus-host disease in USA (IV)
  • 18 Jul 2016 Biomarkers information updated
  • 11 Sep 2013 Swedish Orphan Biovitrum amends its licensing agreement to include palifermin development for a potential new indication
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top